Algorae Pharmaceuticals Limited · ASX:1AI

David Hainsworth received 30,000,003 Algorae Pharmaceuticals Limited shares as an award (Appendix 3Y, ASX)

Traded Nov 11, 2026 · Filed Nov 11, 2026

On Nov 11, 2026, David Hainsworth (Director) received 30,000,003 Algorae Pharmaceuticals Limited shares as an award. Filed Nov 11, 2026 (Appendix 3Y, ASX).

Awarded
30,000,003 shares
Role
Director

The filing in full

Appendix 3Y

*Rule 3.19A.2*

Change of Director’s Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and
documents given to ASX become ASX’s property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

Name of entityAlgorae Pharmaceuticals Limited (ASX:1AI)
ABN14 104 028 042

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the
director for the purposes of section 205G of the Corporations Act.

Name of DirectorDavid Hainsworth
Date of last notice30 September 2026

Part 1 - Change of director’s relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be
disclosed in this part.

Direct or indirect interestIndirect 1
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.Indirect 1 Union Square Capital Pty Ltd Indirect 2 Cathedral Estate Pty Ltd
Date of change11 November 2026
  • See chapter 19 for defined terms.

---

No. of securities held prior to changeDirect (a) 20,000,000 fully paid ordinary shares; (b) 20,000,000 performance rights (AGM 2024); (c) 30,000,000 performance rights (AGM 2025); and (d) 4,000,000 unlisted options, each with an exercise price of $0.014 and expiring on 1 December 2029. Indirect 1 Union Square Capital Pty Ltd , an entity in which Mr Hainsworth is a director and controlling shareholder: (a) Nil Indirect 2 Cathedral Estate Pty Ltd , an entity in which Mr Hainsworth is a director and controlling shareholder: (a) 5,937,500 fully paid ordinary shares; and (b) 1,125,000 unlisted options, each with an exercise price of $0.014 and expiring on 1 December 2029.
ClassPerformance Rights
Number acquiredIndirect 1 30,000,000
Number disposedNil
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuationNil
  • See chapter 19 for defined terms.

---

No. of securities held after changeDirect (a) 20,000,000 fully paid ordinary shares; (b) 20,000,000 performance rights (AGM 2024); (c) 30,000,000 performance rights (AGM 2025); and (d) 4,000,000 unlisted options, each with an exercise price of $0.014 and expiring on 1 December 2029. Indirect 1 Union Square Capital Pty Ltd , an entity in which Mr Hainsworth is a director and controlling shareholder: (a) 30,000,000 performance rights (AGM 2026). Indirect 2 Cathedral Estate Pty Ltd , an entity in which Mr Hainsworth is a director and controlling shareholder: (a) 5,937,500 fully paid ordinary shares; and (b) 1,125,000 unlisted options, each with an exercise price of $0.014 and expiring on 1 December 2029.
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-backIssue of Performance Rights following shareholder approval at the Annual General Meeting held on 5 November 2026.

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be
disclosed in this part.

Detail of contractN/A
Nature of interestN/A
Name of registered holder (if issued securities)N/A
Date of changeN/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changedN/A

---

Appendix 3Y
Change of Director’s Interest Notice

Interest acquiredN/A
Interest disposedN/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuationN/A
Interest after changeN/A

+
Part 3 – Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?No
If so, was prior written clearance provided to allow the trade to proceed during this period?N/A
If prior written clearance was provided, on what date was this provided?N/A
  • See chapter 19 for defined terms.

---

Appendix 3Y

*Rule 3.19A.2*

Change of Director’s Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and
documents given to ASX become ASX’s property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

Name of entityAlgorae Pharmaceuticals Limited (ASX:1AI)
ABN14 104 028 042

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the
director for the purposes of section 205G of the Corporations Act.

Name of DirectorDavid Gulland
Date of last notice12 March 2026

Part 1 - Change of director’s relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be
disclosed in this part.

Direct or indirect interestIndirect 2
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.Indirect 1 Mrs Rachelle Gulland Indirect 2 Gull Health Pty Ltd
Date of change11 November 2026
  • See chapter 19 for defined terms.

---

No. of securities held prior to changeIndirect 1 Mrs Rachelle Gulland, spouse of Mr David Gulland: (a) 3,279,333 fully paid ordinary shares; and (b) 655,866 unlisted options, each with an exercise price of $0.014 and expiring on 1 December 2029. Indirect 2 Gull Health Pty Ltd , an entity in which Mr Gulland is a director and controlling shareholder: (a) 1,666,667 fully paid ordinary shares; (b) 15,000,000 unlisted options, each with an exercise price of $0.014 and expiring on 1 December 2029; and (c) 42,000,000 performance rights.
ClassPerformance Rights
Number acquiredIndirect 2 30,000,000
Number disposedNil
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuationNil
No. of securities held after changeIndirect 1 Mrs Rachelle Gulland, spouse of Mr David Gulland: (a) 3,279,333 fully paid ordinary shares; and (b) 655,866 unlisted options, each with an exercise price of $0.014 and expiring on 1 December 2029. Indirect 2 Gull Health Pty Ltd , an entity in which Mr Gulland is a director and controlling shareholder: (a) 1,666,667 fully paid ordinary shares; (b) 15,000,000 unlisted options, each with an exercise price of $0.014 and expiring on 1 December 2029; (c) 42,000,000 performance rights; and (d) 30,000,000 performance rights (2026 AGM).

---

Nature of changeExample: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-backIssue of Performance Rights following shareholder approval at the Annual General Meeting held on 5 November 2026.

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be
disclosed in this part.

Detail of contractN/A
Nature of interestN/A
Name of registered holder (if issued securities)N/A
Date of changeN/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changedN/A
Interest acquiredN/A
Interest disposedN/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuationN/A
Interest after changeN/A

+
Part 3 – Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?No
If so, was prior written clearance provided to allow the trade to proceed during this period?N/A
If prior written clearance was provided, on what date was this provided?N/A
  • See chapter 19 for defined terms.

---

Appendix 3Y

*Rule 3.19A.2*

Change of Director’s Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and
documents given to ASX become ASX’s property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

Name of entityAlgorae Pharmaceuticals Limited (ASX:1AI)
ABN14 104 028 042

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the
director for the purposes of section 205G of the Corporations Act.

Name of DirectorTroy Valentine
Date of last notice21 July 2026

Part 1 - Change of director’s relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be
disclosed in this part.

Direct or indirect interestDirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.Indirect 1 Valplan Pty Ltd Indirect 2 Citieside Investments Pty Ltd Indirect 3 Alignment Capital Pty Ltd
Date of change11 November 2026
  • See chapter 19 for defined terms.

---

No. of securities held prior to changeDirect (a) Nil. Indirect 1 Valplan Pty Ltd , an entity which Mr Valentine has an equitable interest in: (a) 15,000,000 fully paid ordinary shares; and (b) 4,960,000 unlisted options, each with an exercise price of $0.014 and expiring on 1 December 2029. Indirect 2 Cityside Investments Pty Ltd, an entity which Mr Valentine has an equitable interest in: (a) 4,150,000 fully paid ordinary shares; and (b) 1,030,000 unlisted options, each with an exercise price of $0.014 and expiring on 1 December 2029. Indirect 3 Alignment Capital Pty Ltd, an entity which Mr Valentine has an equitable interest in: (a) 20,500,000 fully paid ordinary shares; and (b) 4,100,000 unlisted options, each with an exercise price of $0.014 and expiring on 1 December 2029.
ClassPerformance Rights
Number acquiredDirect 30,000,000
Number disposedNil
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuationNil
  • See chapter 19 for defined terms.

---

No. of securities held after changeDirect (a) 30,000,000 performance rights (2026 AGM). Indirect 1 Valplan Pty Ltd , an entity which Mr Valentine has an equitable interest in: (a) 15,000,000 fully paid ordinary shares; and (b) 4,960,000 unlisted options, each with an exercise price of $0.014 and expiring on 1 December 2029. Indirect 2 Cityside Investments Pty Ltd, an entity which Mr Valentine has an equitable interest in: (a) 4,150,000 fully paid ordinary shares; and (b) 1,030,000 unlisted options, each with an exercise price of $0.014 and expiring on 1 December 2029. Indirect 3 Alignment Capital Pty Ltd, an entity which Mr Valentine has an equitable interest in: (a) 20,500,000 fully paid ordinary shares; and (b) 4,100,000 unlisted options, each with an exercise price of $0.014 and expiring on 1 December 2029.
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-backIssue of Performance Rights following shareholder approval at the Annual General Meeting held on 5 November 2026.

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be
disclosed in this part.

Detail of contractN/A
Nature of interestN/A
Name of registered holder (if issued securities)N/A
Date of changeN/A
  • See chapter 19 for defined terms.

---

No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changedN/A
Interest acquiredN/A
Interest disposedN/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuationN/A
Interest after changeN/A

+ Part 3 – Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?No
If so, was prior written clearance provided to allow the trade to proceed during this period?N/A
If prior written clearance was provided, on what date was this provided?N/A
  • See chapter 19 for defined terms.
DateSecurityTransactionSharesPriceHolding afterOwnership
Nov 11, 2026Performance RightsAward1
Nov 11, 2026Performance RightsAward2
Nov 11, 2026Performance RightsAward30,000,000

Source

Download PDF · View original at ASX

Related